Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Specimen Handling 454Magnetic Resonance Spectroscopy 347pembrolizumab 289Biopsy 244Carboplatin 230Cisplatin 194Cyclophosphamide 186Paclitaxel 164Nivolumab 154Gemcitabine 151Radiotherapy 125Bevacizumab 124Dexamethasone 113fludarabine 100Pemetrexed 99Fluorouracil 94Doxorubicin 92durvalumab 91Radiation 91Docetaxel 91venetoclax 89Rituximab 88Oxaliplatin 88atezolizumab 87Leucovorin 79Capecitabine 76Prednisone 75Lenalidomide 70Etoposide 69X-Rays 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Glutamate Carboxypeptidase II × 30 days × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT06632977 2026-06-02

PREDICT

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
474 enrolled
Genitourinary

Prostatic Neoplasms

NCT07468903 2026-05-22

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Jonsson Comprehensive Cancer Center

Phase NA Recruiting
45 enrolled
Genitourinary

Prostatic Neoplasms

NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡